Citations

Clear

9 citation(s) found for "Zhang, Zhenmei".

Characterization of patients with restrictive patterns of lung disease following allogeneic hematopoietic stem cell transplantation
Gaur, Gunjan, Zhang, Zhenmei, Yadav, Hemang, Gaur, Gunjan, Zhang, Zhenmei, Yadav, Hemang

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6064-6064

10.1182/blood-2025-6064 Get It

Abstract Background: As mounting numbers of patients receive allogeneic hematopoetic stem cell transplantation (allo-SCT) for hematologic malignancies, focus on survivorship and post-transplant complications is increasing. 30-60% of patients develop pulmonary complications, making the lungs the most affected organ post-transplant. While obstructive lung disease post-allo-SCT has been studied as a manifestation of graft-versus-host-disease (GVHD) in the form of bronchiolitis obliterans syndrome, many patients' post-transplant pulmonary function tests (PFTs) reveal restrictive patterns of disease which have been understudied. The pathophysiology, risk factors, and clinical course of restrictive lung disease (RLD) post-allo-SCT have not been fully elucidated. This retrospective study sought to characterize baseline characteristics, imaging findings, and possible risk factors of patients with RLD post-allo-SCT. Methods: The study included all patients receiving allo-SCT at our institution between 2005 and 2021 with at least one screening PFT with a restrictive pattern. Restriction is defined as normal forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio and total lung capacity (TLC) less than the lower limit of normal. Data collected via chart review included demographic information; indication for and type of transplant; myeloablative or nonmyeloablative conditioning; pre-existing lung disease; history of lung or chest-wall irradiation; acute post-transplant complications; documented acute or chronic graft-versus-host-disease (GVHD) of the lungs, skin, or other organs; and chest imaging findings on x-ray or computed tomography. For patients with at least two PFTs (n=168), average rate of change of TLC since transplant was calculated. Average monthly change in TLC post-transplant was compared between multiple groups detailed under Results. Analysis of variance or unpaired t-test and linear regression were used for comparison of categorical and continuous variables, respectively. Statistical analyses were completed using BlueSky Statistics 10.3.4, R version 4.1.3. Results: 234 patients were included. Median age at transplant was 51 years (range 18-74), and 163 (70%) were male. Average BMI at transplant was 29.6 (17.9–51.4). 107 (46.3%) underwent myeloablative conditioning, and 124 (53.2%) underwent reduced intensity or nonmyeloablative regimens. The most common indications for transplant were AML (n=87), MDS (n=41), and ALL (n=40). Most had no pre-existing lung disease (n=131, 56.2%), and 61 (26.1%) had evidence of restriction on pre-transplant PFTs. About half (n=119, 51.1%) had a history of lung or chest-wall irradiation. Within 30-days post-transplant, 55 (23.5%) had pulmonary complications (pneumonia or other hypoxic respiratory failure). 151 (64.8%) had either acute or chronic skin GVHD; 91 (39.1%) carried diagnoses of pulmonary GVHD. Most common associated imaging findings were infiltrates (n=120), scarring/atelectasis (n=73), pleural effusion (n=62), and air-trapping (n=50). Mean rate of change in TLC following transplant among all subjects was -0.0473 L/month. Comparative analysis revealed no statistically significant differences in mean values of average change in TLC between those with myeloablative and nonmyeloablative regimens (-0.0733 vs -0.0227 L/month, p = 0.176); pulmonary GVHD or not (-0.0752 vs -0.0203 L/month, p=0.141); GVHD or not (-0.0514 vs -0.0373 L/month, p=0.731); or with or without prior chest irradiation (-0.0234 vs -0.0687 L/month, p=0.226). Women had, on average, positive change in TLC compared to men (+0.00963 vs -0.0709 L/month, p=0.049). Decline in TLC was faster in overweight or obese patients (p=0.006). Conclusion: Our study establishes and describes a cohort of patients with restrictive lung disease post-allo-SCT, a poorly understood and incompletely characterized, yet highly morbid, set of diverse entities into which our findings provide insight. Based on the descriptive analysis we completed, patients experience decline in TLC due to a variety of processes – infiltrative pathology, pleural effusions, and chest wall weakness/restriction. Rate of decline increases with BMI and male gender. Diagnosis of pulmonary GVHD does not seem related to progression of restriction. As more long-term data is obtained from screening PFTs, examining larger datasets may allow for more granular analysis of the numerous possible etiologies.
Acute Respiratory Distress Syndrome Phenotypes After Stem Cell Transplantation: A Latent Class Analysis
Herasevich, Svetlana , Heybati, Kiyan , Zhang, Zhenmei , Pennington, Kelly M. , Calfee, Carolyn S. , Yadav, Hemang , Yadav, Hemang , Hogan, William J. , Hefazi, Mehrdad , Alkhateeb, Hassan B. , Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | September 6, 2025 | Volume: 7 | Issue: 9 | Pages: e1312

10.1097/cce.0000000000001312 | PMID 40913014 Get It

OBJECTIVE: To identify distinct phenotypes of acute respiratory distress syndrome (ARDS) developing after hematopoietic cell transplantation (HCT), using routinely available clinical data at ICU admission. DESIGN: Multicenter retrospective cohort study using latent class analysis. SETTING: ICUs across three Mayo Clinic campuses (Minnesota, Florida, and Arizona). PATIENTS: A total of 166 adult patients who developed ARDS within 120 days following HCT (96 allogeneic, 70 autologous). INTERVENTION: None. MEASUREMENTS AND MAIN RESULTS: Model selection was based on multiple metrics including Bayesian information criteria, entropy, and Vuong-Lo-Mendell-Rubin Likelihood Ratio testing. A two-class model optimally described the cohort. Class 1 (n = 81) was characterized by worse hypoxemia (P/F ratio 157 vs. 210, p = 0.002), higher Pco 2 (41 vs. 36 mm Hg, p < 0.001), and higher bilirubin (1.4 vs. 0.9 mg/dL, p < 0.001) compared with class 2 (n = 85). Both classes included a mix of transplant types, transcending a simple autologous/allogeneic dichotomy, although class 1 had more allogeneic recipients (70.4% vs. 45.9%, p = 0.001). Although time-from-transplant was not a class-defining variable, class 1 occurred later after transplant (30.0 vs. 11.9 d, p < 0.001) with higher frequency of idiopathic pneumonia syndrome (14.8% vs. 2.4%, p = 0.004). Class 2 had more frequent neutropenia (leukocytes 0.4 vs. 5.9 × 109, p < 0.001) and higher frequency of peri-engraftment respiratory distress syndrome (29.4% vs. 9.9%, p = 0.005). Outcomes were significantly worse for class 1 (90-d mortality: 72.8% vs. 48.2%, p = 0.001). An exploratory parsimonious model had good classification accuracy (0.90) using just six variables: leukocyte count, platelet count, bilirubin, Pco 2, body mass index, and temperature. CONCLUSIONS: ARDS after HCT comprises two distinct phenotypes with distinct clinical characteristics and outcomes. These phenotypes align with recognized post-HCT lung injury syndromes and may reflect different underlying biological processes. This framework provides a foundation for investigating targeted therapeutic approaches.
Risk of Bronchiolitis Obliterans Among Bone Marrow Transplant Recipients Who Received Post-Transplant Cyclophosphamide Compared to Standard of Care
Eggleston, R., Yadav, H., Pennington, Kelly M. , Zhang, Zhenmei , Eggleston, R.H., Alkhateeb, Hassan B.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1126-A1126

10.1164/ajrccm.2025.211.abstracts.a1126 Get It

Abstract RATIONALE: Allogeneic hematopoietic stem cell transplant (alloHSCT) is the only curative therapy for multiple hematological malignancies and bone marrow failure syndromes. Graft versus host disease (GvHD), remains one of the leading causes of morbidity and mortality. Bronchiolitis obliterans syndrome (BOS) is the canonical manifestation of chronic GvHD of the lungs, occurring in 3-10% of alloHSCT recipients and conferring poor prognosis. There has been a recent paradigm shift towards using post-transplant cyclophosphamide (PTCy) for GvHD prophylaxis resulting in dramatic decreases in both acute and chronic GvHD compared to traditional regimens using methotrexate and tacrolimus. The effect of PTCy on the development of BOS is not well-studied. METHODS: We performed a retrospective cohort study comparing the cumulative incidence of BOS between 93 patients receiving PTCy and 154 patients receiving non-PTCy containing regimens for GvHD prophylaxis between 2015 and 2023 at a single center (Mayo Clinic, Rochester, MN). Patients were included if they were ever diagnosed with BOS or if they survived and were followed for at least 1 year. BOS was diagnosed using 2014 National Institutes of Health criteria. Patients who met 3 of 4 diagnostic criteria were included if a clinical diagnosis of BOS was made. We performed a competing risks time-to-event analysis to compare the incidence of BOS (or death) between the two cohorts. Outcomes were not adjusted for HSCT type (related, unrelated, or haploidentical [HID]) due to a high degree of collinearity with GvHD prophylaxis strategy. RESULTS: Combined cohorts were median age 55 (40-63), 56% male, and 43% ever smokers. Transplants involved HID donors (59% of PTCy cohort, zero non-PTCy), matched related (10% of PTCy, 44% of non-PTCy), matched unrelated (20% of PTCy, 51% of non-PTCy), and mismatched unrelated donors (11% of PTCy, 5% of non-PTCy). Three-year cumulative incidences of BOS among PTCy and non-PTCy recipients were 7% and 14%, respectively (subdistribution HR 0.52 [95% CI 0.21-1.29], P=0.159). For those who received PTCy, incidence of GvHD was smaller (subdistribution HR 0.64 [95% CI 0.46-0.99], P=0.006) with fewer organs involved (1 versus 2, P=&lt;0.0001) and fewer immunosuppressive therapies employed for treatment (2.0 versus 2.5, P=0.01). CONCLUSION: PTCy may reduce risk of BOS among patients undergoing HSCT. Findings are limited by important differences between the cohorts, such as HCT type, and by small sample size. As PTCy is now increasingly used for non-HID transplants, future studies are needed to examine the effect of PTCy on the development of BOS.
Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study
Herasevich, Svetlana , Schulte, Phillip J. , Zhang, Zhenmei , Khera, Nandita , Yadav, Hemang , Zhang, Zhenmei , White, Bradley A , Yadav, Hemang , Hogan, William J. , Alkhateeb, Hassan B. , White, Bradley A., Roy, Vivek , Gajic, Ognjen

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | December 5, 2023 | Volume: 209 | Issue: 5 | Pages: 543-552

10.1164/rccm.202308-1524oc | PMID 38051944 Get It

Abstract Rationale Pulmonary complications contribute significantly to nonrelapse mortality following hematopoietic stem cell transplantation (HCT). Identifying patients at high risk can help enroll such patients into clinical studies to better understand, prevent, and treat posttransplantation respiratory failure syndromes. Objectives To develop and validate a prediction model to identify those at increased risk of acute respiratory failure after HCT. Methods Patients underwent HCT between January 1, 2019, and December 31, 2021, at one of three institutions. Those treated in Rochester, MN, formed the derivation cohort, and those treated in Scottsdale, AZ, or Jacksonville, FL, formed the validation cohort. The primary outcome was the development of acute respiratory distress syndrome (ARDS), with secondary outcomes including the need for invasive mechanical ventilation (IMV) and/or noninvasive ventilation (NIV). Predictors were based on prior case-control studies. Measurements and Main Results Of 2,450 patients undergoing stem cell transplantation, there were 1,718 hospitalizations (888 patients) in the training cohort and 1,005 hospitalizations (470 patients) in the test cohort. A 22-point model was developed, with 11 points from prehospital predictors and 11 points from posttransplantation or early (&lt;24-h) in-hospital predictors. The model performed well in predicting ARDS (C-statistic, 0.905; 95% confidence interval [CI], 0.870–0.941) and the need for IMV and/or NIV (C-statistic, 0.863; 95% CI, 0.828–0.898). The test cohort differed markedly in demographic, medical, and hematologic characteristics. The model also performed well in this setting in predicting ARDS (C-statistic, 0.841; 95% CI, 0.782–0.900) and the need for IMV and/or NIV (C-statistic, 0.872; 95% CI, 0.831–0.914). Conclusions A novel prediction model incorporating data elements from the pretransplantation, posttransplantation, and early in-hospital domains can reliably predict the development of post-HCT acute respiratory failure.
Predictive Value of Spirometry Z-Scores for the Development of Pulmonary Complications After Hematopoietic Stem Cell Transplantation
White, B A, Zhang, Zhenmei , Torghabeh, Mehrdad Hefazi, Yadav, H., White, B.A., Herasevich, Svetlana , Hefazi, Mehrdad

Mayo Clinic

B70. INHALE THE FUTURE: NEW FINDINGS IN PULMONARY FUNCTION | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A4093-A4093

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4093 Get It

Exercise Oximetry and Pulmonary Complication Risk in Stem Cell Transplant Recipients
Zhang, Zhenmei , Yadav, H., Herasevich, Svetlana

Mayo Clinic

B70. INHALE THE FUTURE: NEW FINDINGS IN PULMONARY FUNCTION | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A4077-A4077

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4077 Get It

Mediastinal Infection After Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
Marty, Paige K. , Temesgen, Zelalem , Nelson, Darlene R. , Yetmar, Zachary A. , Zhang, Zhenmei

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | February 2, 2023 | Volume: 30 | Issue: 3 | Pages: 307-310

10.1097/lbr.0000000000000909 | PMID 36729086 Get It

1322: A QUALITY IMPROVEMENT INITIATIVE TO IMPROVE ROUNDING IN THE MEDICAL INTENSIVE CARE UNIT
Veerabattini, N., Breighner, Crystal , Frank, Ryan D. , Zhang, Zhenmei , Myers, Melissa A , Niven, Alexander S.

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 638-638

10.1097/01.ccm.0000645204.78670.8a Get It

591: DON’T OVERLOOK THAT TICK BITE
Best, Patricia J.M. , Zhang, Zhenmei

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 276-276

10.1097/01.ccm.0000551343.23322.03 Get It